A bonanza of new state psychedelics bills, including ones to fund ibogaine research and new trigger laws for synthetic psilocybin

US state governments are advancing new psychedelic policy bills focused on ibogaine research funding, psilocybin trigger laws for synthetic products, and state managed psychedelic programs. The newsletter highlights ibogaine bills in Tennessee, Maryland, and Vermont aimed at creating state funds and advisory structures to support medicalization and future clinical trials. It also covers psilocybin trigger legislation in New Mexico and a broader Colorado bill that change state rules if any Schedule I drug is approved for prescription use, alongside Washington proposals for a state overseen medical psilocybin program. It also reports a death and other concerns tied to an ibogaine clinic in Mexico, including discussion of potential complications and screening changes related to fentanyl exposure. Finally, MAPS releases a policy guide emphasizing consumer protection, cautious use of the term “therapy,” and regulatory approaches to address trigger laws and bifurcated scheduling.